A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)

Phase 1 Terminated 27 enrolled Merck Sharp & Dohme LLC

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of MK-0457(VX-680), an Aurora kinase inhibitor, in participants with advanced solid tumors. Bioavailability of the oral formulation will also be assessed. The primary study hypothesis is that administration of MK-0457 is sufficiently safe and tolerated to permit further study.

Timeline

Start: 2005-05
Primary completion: 2008-01
Completion: 2008-01

Publications

Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Feb;67(2):305-14. doi: 10.1007/s00280-010-1318-9. Epub 2010 Apr 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOZASERTIB	Small molecule	64 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	96 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	100 mg	Intravenous

A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)

Summary

Timeline

Publications

Drugs

Indications